Drug Profile
YY CEM
Alternative Names: YY-CEMLatest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Yuyu
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in South Korea
- 02 Feb 2021 YY CEM is still in preclinical trial for Rheumatoid arthritis in South Korea (Yuyu pipeline, February 2021)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in South Korea